Carcinogenesis Advance Access originally published online on April 1, 2004
Carcinogenesis 2004 25(8):1485-1494; doi:10.1093/carcin/bgh154
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Carcinogenesis vol.25 no.8 © Oxford University Press 2004; all rights reserved.
ARTICLE |
Overexpression of tumour suppressor retinoblastoma 2 protein (pRb2/p130) in hepatocellular carcinoma
Laboratory of Molecular Endocrinology, Division of Cellular and Molecular Research, National Cancer Centre of Singapore, Singapore 169610
Tel: +65 436 8347; Fax: +65 226 5694; Email: cmrhth{at}nccs.com.sg
Hepatocellular carcinoma (HCC) is one of the most common malignancies in Southeast Asia. Although inactivation of pRb2/p130 has been reported in a variety of human cancers, its function in HCC has not been established. In this study we report that loss of expression of pRb2/p130 was detected by immunohistochemistry and western blotting in 15.2% (7 of 46) HCCs examined. High levels of pRb2/p130 expression were found in 84.8% (39 of 46) HCCs studied. Western blot analysis revealed that HCC had 3.5-fold higher pRb2/p130 than adjacent benign liver (ABL) tissues. 71.7% (33 of 46) of HCCs examined exhibited both nuclear and cytoplasmic staining for pRb2/p130. Cytoplasmic staining was found in 93.5% (43 of 46) of ABL tissues. Overproduction of pRb2/p130 in HepG2 cells led to growth suppression, cell cycle arrest in G0/G1, altered cell morphology, inhibition of in vitro colony formation and reduction in tumourigenicity in SCID mice. This demonstration suggests a role of pRb2/p130 as a tumour suppressor protein in HCC and the loss of this protein may lead to the development or progression of HCC. Overexpression of pRb2/p130 in HCC was, therefore, suggested to be a programmed protective response of the organism to uncontrolled proliferation.
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
M. Katzenellenbogen, L. Mizrahi, O. Pappo, N. Klopstock, D. Olam, J. Jacob-Hirsch, N. Amariglio, G. Rechavi, E. Domany, E. Galun, et al. Molecular Mechanisms of Liver Carcinogenesis in the Mdr2-Knockout Mice Mol. Cancer Res., November 1, 2007; 5(11): 1159 - 1170. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Huynh, K. C. Soo, P. K.H. Chow, L. Panasci, and E. Tran Xenografts of Human Hepatocellular Carcinoma: A Useful Model for Testing Drugs. Clin. Cancer Res., July 15, 2006; 12(14): 4306 - 4314. [Abstract] [Full Text] [PDF] |
||||

